– Bloomberg
Piper Sandler Maintains Overweight on argenx, Raises Price Target to $465
Piper Sandler analyst Allison Bratzel maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $450 to $465.
Related Posts
Jabil Analysts Boost Their Forecasts After Strong Q3 Results
Jabil Inc (NYSE: JBL) reported better-than-expected third-quarter financial results.
ZyVersa Therapeutics, Inc. Announces Pricing Of $11M Public Offering Of $11.015,500 Shares Of Common Stock At A Price Of $1/Share
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, or ", ZyVersa", )))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, today
